US2017354727A1PendingUtilityA1
Modulation of replicative fitness by deoptimization of synonymous codons
Assignee: THE GOVERNMENT OF THE USA AS REPRESENTED BY THE SECRETARY OF THE DEPT OF HEALTH AND HUMAN SERVICEPriority: Oct 8, 2004Filed: Aug 23, 2017Published: Dec 14, 2017
Est. expiryOct 8, 2024(expired)· nominal 20-yr term from priority
A61P 37/00C12N 2710/16162C12N 2710/16762C12N 2770/20062C12N 2760/18562A61K 2039/5254C07K 14/245C12N 15/67C12N 7/00C12N 2710/16662C12N 2770/36262C12N 2770/24162C12N 2770/32762C12N 2760/18462A61K 2039/522C12N 2760/16162A61K 39/0258C12N 2770/32162Y02A50/30A61K 39/00
57
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Methods of producing a pathogen with reduced replicative fitness are disclosed, as are attenuated pathogens produced using the methods. In particular examples, the method includes deoptimizing one or more codons in a coding sequence, thereby reducing the replicative fitness of the pathogen. Methods of using the attenuated pathogens as immunogenic compositions are also disclosed.
Claims
exact text as granted — not AI-modifiedWe claim:
1 . A method of attenuating a bacterium, comprising preparing a bacterial nucleic acid molecule comprising at least twenty deoptimized codons in a coding sequence of the bacterium by replacing each of the at least twenty codons in the coding sequence with a synonymous codon less frequently used in the bacterium, thereby generating an attenuated bacterium comprising a deoptimized bacterial nucleic acid molecule.
2 . The method of claim 1 , wherein the bacterial nucleic acid molecule comprises replacement of at least 50-2000 codons with synonymous codons less frequently used in the bacterium.
3 . The method of claim 1 , wherein replicative fitness of the attenuated bacterium is reduced by at least 20% as compared to an amount of replicative fitness by the bacterium having a coding sequence with a native codon composition.
4 . The method of claim 1 , wherein replicative fitness of the attenuated bacterium is reduced by 10-98% as compared to replicative fitness of the bacterium with a native codon composition.
5 . The method of claim 1 , wherein the deoptimized bacterial nucleic acid molecule comprises replacement of at least 50% of the coding sequence with synonymous codons less frequently used in the bacterium.
6 . The method of claim 1 , wherein the deoptimized bacterial nucleic acid molecule alters the number of CG dinucleotides, the number of TA dinucleotides, or the number of CG dinucleotides and TA nucleotides in the coding sequence by at least 20%.
7 . The method of claim 6 , wherein the deoptimized bacterial nucleic acid molecule increases the number of CG dinucleotides or TA dinucleotides in the coding sequence by at least 100%.
8 . The method of claim 1 , wherein the deoptimized bacterial nucleic acid molecule comprises a coding sequence having an increased number of CG dinucleotides, TA dinucleotides, or CG dinucleotides and TA nucleotides in the coding sequence, wherein the CG or TA dinucleotides fall across codon boundaries.
9 . The method of claim 1 , wherein the deoptimized bacterial nucleic acid molecule is introduced into the bacterial genome.
10 . The method of claim 1 , wherein the bacterium is a gram-negative bacterium.
11 . The method of claim 10 , wherein the gram-negative bacterium is Escherichia coli, Shigella dysenteriae , or Vibrio cholerae.
12 . The method of claim 11 , wherein the bacterium is E. coli and wherein at least 20 codons in an ArgS or TufA coding sequence are deoptimized or the bacterium is Shigella dysenteriae and at least 20 codons in a RdsB coding sequence are deoptimized.
13 . The method of claim 12 , wherein the deoptimized coding sequence comprises a sequence having at least 90% sequence identity to SEQ ID NO: 48 or SEQ ID NO: 51.
14 . The method of claim 13 , wherein the deoptimized coding sequence comprises a sequence shown in SEQ ID NO: 48 or SEQ ID NO: 51.
15 . The method of claim 1 , wherein the bacterium is a gram-positive bacterium.
16 . The method of claim 15 , wherein the gram-positive bacterium is Bacillus anthracis, Staphylococcus aureus , pneumococcus, gonococcus, or streptococcal meningitis.
17 . The method of claim 16 , wherein the bacterium is Staphylococcus aureus and at least twenty codons in an RplB or FusA coding sequence are deoptimized.Join the waitlist — get patent alerts
Track US2017354727A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.